

RSV vaccines indicator

Acceptability to stakeholders

Acceptability of the vaccine and of vaccination against the disease

The acceptability of maternal tetanus vaccines is generally high in LMICs. Acceptance of other maternal vaccines depends on the perception of safety to the infant. ¹

Acceptability of RSV maternal vaccine is dependent on increasing the awareness of RSV. If key stakeholders are provided with reliable evidence to demonstrate the benefits of the RSVpre-F vaccine, it is likely to be acceptable. However, the cost of RSV vaccination is likely to influence how countries will prioritize its introduction relative to other vaccines or public health interventions. ²

For nirsevimab, acceptability to key stakeholders will depend on whether the price of the product is affordable in the country. Wide use of mAbs for passive immunization has never been implemented in LMICs. ³

Sources

1.

SAGE EtR tables (2024). September 2024. Geneva: World Health Organization
(https://territance.who.int/mediacentre/data/sage/SAGE_eYB_Sept2024.pdf, accessed 20 June 2025).

2.

Fleming JA, Baral R, Higgins D, Khan S, Kochar S, Li Y, et al. (2023). Value profile for respiratory syncytial virus vaccines and monoclonal antibodies. *Vaccine*. 41(Suppl 1):S7.
doi:10.1016/j.vaccine.2022.09.081.

3.

Limaye RJ, Sauer M, Njogu R, Singh P, Fesshaye B, Karron RA (2023). Characterizing attitudes toward maternal RSV vaccines among pregnant and lactating persons in Kenya: key considerations for demand generation efforts for vaccine acceptance. *J Pediatric Infect Dis Soc*. 12:638–41.